Tissuetech, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tissuetech, Inc. - overview
Established
2001
Location
Miami, FL, US
Primary Industry
Biotechnology
About
Tissuetech, Inc. is a biotechnology company focused on developing innovative regenerative healing solutions utilizing proprietary technologies to enhance tissue repair and recovery in various medical fields. Founded in 2001 and headquartered in Miami, US, Tissuetech, Inc. specializes in regenerative medicine solutions.
The company raised USD 82. 25 mn in Series C funding in April 2019, led by Essex Woodlands with participation from Ballast Point Ventures. Amy Tseng is the founder, and Ted Davis serves as the CEO. Tissuetech specializes in advanced regenerative healing solutions through its CryoTek® technology, preserving the structure and biological properties of human birth tissue allografts.
Its core products include Prokera, AmnioGraft, AmnioGuard, and Neox, primarily used in ophthalmology and surgical settings to support tissue repair and regeneration. The company serves healthcare providers, hospitals, and surgical centers across the US and selected regions in Europe and Asia. Tissuetech generates revenue through direct sales of its regenerative medicine products to healthcare facilities and practitioners. The revenue model focuses on B2B partnerships with hospitals and medical organizations that utilize its allografts in clinical settings, with products priced to reflect their therapeutic benefits and market demand.
Tissuetech plans to introduce upcoming products designed to enhance tissue regeneration solutions. The company is targeting expansion into specific markets in Europe and Asia by 2025. The recent funding of USD 82. 25 mn from the Series C round will support these initiatives, including product development and market entry strategies.
Current Investors
Ballast Point Ventures, Essex Woodlands, RC Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.tissuetech.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Tissuetech, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.